Preliminary data from a phase 1/2 trial indicate that Principia Biopharma’s BTK inhibitor Rilzabrutinib could treat immune thrombocytopenia.
The team of Dr. Katerina Akassoglou at Gladstone Institutes and UCSF studied the gene signature of pathogenic innate immune cells in the CNS.
Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Dupixent (dupilumab), developed by Regeneron and Sanofi, has shown “significant efficacy” for Eosinophilic Esophagitis in a phase 3 trial.
The European Commission approved subcutaneous Entyvio as a maintenance therapy for adults with Ulcerative Colitis or Crohn’s Disease.
Navidea Biopharmaceuticals’ phase 2B NAV3-31 clinical trial is evaluating Tc99m Tilmanocept Planar Imaging in rheumatoid arthritis patients.
Gilead JAK1 inhibitor Filgotinib 200 mg was shown to more effectively induce and maintain ulcerative colitis remission than a placebo.
A physician, Dr. Giovanni Monteleone MD PhD, outlines the implications of COVID-19 for Ulcerative Colitis and Crohn’s Disease patients.
Regulatory T cells control fibroblast activation in skin to suppress the pathogenesis of tissue fibrosis
The activity and function of regulatory T cells (Tregs) largely depends on the tissue in which they reside. Recent research has identified that Tregs in the skin are primed to control the pathogenesis of tissue fibrosis by expressing a unique transcriptional signature that supports the effective suppression of type 2 immune responses.
Knocking out a form of the liver X receptor, a protein involved in the regulation of gene expression, was found to promote inflammation and the loss of protective proteins in the blood-brain barrier, suggesting that the upregulation of these receptors could be considered as an approach to Multiple Sclerosis treatment.